PuSH - Publikationsserver des Helmholtz Zentrums München

Export: TXT Text RIS Endnote (RIS) BIB BibTeX
Simpson, E.L.* ; Bruin-Weller, M.* ; Flohr, C.* ; Ardern-Jones, M.R.* ; Barbarot, S.* ; Deleuran, M.* ; Bieber, T.* ; Vestergaard, C.* ; Brown, S.J.* ; Cork, M.J.* ; Drucker, A.M.* ; Eichenfield, L.F.* ; Foelster-Holst, R.* ; Guttman-Yassky, E.* ; Nosbaum, A.* ; Reynolds, N.J.* ; Silverberg, J.I.* ; Schmitt, J.* ; Seyger, M.M.B.* ; Spuls, P.I.* ; Stalder, J.F.* ; Su, J.C.* ; Takaoka, R.* ; Traidl-Hoffmann, C. ; Thyssen, J.P.* ; van der Schaft, J.* ; Wollenberg, A.* ; Irvine, A.D.* ; Paller, A.S.*

When does atopic dermatitis warrant systemic therapy? Recommendations from an expert panel of the International Eczema Council.

J. Am. Acad. Dermatol. 77, 623-633 (2017)
Verlagsversion DOI PMC
Open Access Hybrid
Creative Commons Lizenzvertrag
BACKGROUND: Although most patients with atopic dermatitis (AD) are effectively managed with topical medication, a significant minority require systemic therapy. Guidelines for decision making about advancement to systemic therapy are lacking. OBJECTIVE: To guide those considering use of systemic therapy in AD and provide a framework for evaluation before making this therapeutic decision with the patient. METHODS: A subgroup of the International Eczema Council determined aspects to consider before prescribing systemic therapy. Topics were assigned to expert reviewers who performed a topic-specific literature review, referred to guidelines when available, and provided interpretation and expert opinion. RESULTS: We recommend a systematic and holistic approach to assess patients with severe signs and symptoms of AD and impact on quality of life before systemic therapy. Steps taken before commencing systemic therapy include considering alternate or concomitant diagnoses, avoiding trigger factors, optimizing topical therapy, ensuring adequate patient/caregiver education, treating coexistent infection, assessing the impact on quality of life, and considering phototherapy. LIMITATIONS: Our work is a consensus statement, not a systematic review. CONCLUSION: The decision to start systemic medication should include assessment of severity and quality of life while considering the individual's general health status, psychologic needs, and personal attitudes toward systemic therapies.
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Scopus
Cited By
Altmetric
7.002
0.000
103
115
Tags
Anmerkungen
Besondere Publikation
Auf Hompepage verbergern

Zusatzinfos bearbeiten
Eigene Tags bearbeiten
Privat
Eigene Anmerkung bearbeiten
Privat
Auf Publikationslisten für
Homepage nicht anzeigen
Als besondere Publikation
markieren
Publikationstyp Artikel: Journalartikel
Dokumenttyp Wissenschaftlicher Artikel
Schlagwörter Atopic Dermatitis ; Azathioprine ; Biologic ; Consensus Statement ; Cyclosporine ; Eczema ; Methotrexate ; Quality Of Life ; Systemic Therapy; Quality-of-life; Delayed-type Hypersensitivity; Scorad Po-scorad; Clinical-practice; Fluticasone Propionate; Staphylococcus-aureus; Tacrolimus Ointment; Severity Score; Position Paper; Adult Patients
Sprache
Veröffentlichungsjahr 2017
HGF-Berichtsjahr 2017
ISSN (print) / ISBN 0190-9622
e-ISSN 1097-6787
Zeitschrift Journal of the American Academy of Dermatology : JAAD
Quellenangaben Band: 77, Heft: 4, Seiten: 623-633 Artikelnummer: , Supplement: ,
Verlag Elsevier
Verlagsort New York
Begutachtungsstatus Peer reviewed
Institut(e) Institute of Environmental Medicine (IEM)
POF Topic(s) 30202 - Environmental Health
Forschungsfeld(er) Allergy
PSP-Element(e) G-503400-001
PubMed ID 28803668
DOI 10.1016/j.jaad.2017.06.042
WOS ID WOS:000410627400016
Scopus ID 85028305777
Erfassungsdatum 2017-09-18
[➜Korrektur melden]